preservation with cyclophosphamide To prevent inducing primary ovarian insufficiency in premenopausal women with RMD receiving monthly intravenous CYC, we conditionally recommend monthly gonadotropin-releasing hormone agonist co-therapy. Ovarian insufficiency risk with CYC treatment depends on patient age and cumulative monthly CYC dose Thus far, studies have addressed gonadotropin-releasing hormone agonist co-therapy only in CYC-treated RMD patients who receive CYC monthly by intravenous